ArticleWorld journal of surgical oncology2025
E2F7 promotes ESCC progression and cisplatin resistance through transcriptional activation of DVL3 and the Wnt signaling pathway.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis. While the transcription factor E2F7 has been implicated in cancer development, its specific role in ESCC and its association with cisplatin resistance remain unclear. This study aimed to investigate the expression, function, and underlying mechanism of E2F7 in ESCC progression and cisplatin resistance.
methodsE2F7 expression was examined in ESCC tissues and cell lines using qRT-PCR, and its clinical significance was assessed through survival analysis. Functional roles of E2F7 were evaluated through cell proliferation, migration, and invasion assays. Mechanistic studies included dual-luciferase reporter assays and gene expression analyses to assess E2F7's regulation of DVL3 and activation of the Wnt signaling pathway. The impact of E2F7 on cisplatin sensitivity and apoptosis was also investigated.
resultsE2F7 was significantly upregulated in ESCC tissues and cell lines, and its high expression was associated with advanced tumor stage, metastasis, and poor patient survival. E2F7 overexpression promoted ESCC cell proliferation, migration, and invasion, while knockdown suppressed these malignant behaviors. Mechanistically, E2F7 directly activated DVL3 transcription, thereby activating the Wnt pathway activity. Silencing DVL3 partially reversed the tumor-promoting effects of E2F7. Furthermore, E2F7 knockdown increased cisplatin sensitivity and induced apoptosis, which were reversed by DVL3 overexpression. However, direct ChIP evidence of E2F7 binding to the DVL3 promoter is lacking, representing a limitation of this study.
conclusionsE2F7 promotes ESCC progression and cisplatin resistance by transcriptionally activating DVL3 and activating the Wnt signaling pathway. Targeting the E2F7-DVL3 axis may provide a promising therapeutic strategy for ESCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.